Eisai joins trend to enter Russian pharma market, with Halaven launch

26 March 2013

Japanese drug major Eisai (TYO; 4523, through its EMEA (Europe, Middle East and Africa) unit, has announced it is expanding its operations by establishing a new sales and marketing operation in Russia, a market that has seen a great deal attention from multinational pharmaceutical companies in recent times.

Eisai’s market entry will be based on launching its in-house developed innovative breast cancer treatment, Halaven (eribulin), which is expected to be during the second quarter 2013. Following this, Eisai expects to launch its epilepsy portfolio including: Zonegran (zonisamide) – the first of its drugs to gain approval in Russia (The Pharma Letter June 28, 2012), Exalief (eslicarbazepine acetate), and will seek regulatory approval of Fycompa (perampanel) and Inovelon (rufinamide).

Russian market expected to reach $60 billion by 2020

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK